Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Vital signs study drug infusion CRFs Multiple Sclerosis Tysabri NCT00027300

- 23/01/2017 - 1 Formulaire, 3 Groupes Item, 19 Eléments de données, 1 Langue

Groupes Item: Vital signs 1 hour pre-infusion, study drug infusion, vital signs 1 hour post-infusion

The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. Documentation process: This form is to be obtained in Baseline week 0 and every 4 weeks (week 4 to week 116).

Prodast Dabigatran NCT02507856 dropout

- 17/09/2021 - 1 Formulaire, 1 Groupe Item, 12 Eléments de données, 1 Langue

Groupe Item: Studienabbruch

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the drop-out form. https://clinicaltrials.gov/ct2/show/NCT02507856

Prodast Dabigatran NCT02507856 Inclusion

- 17/09/2021 - 1 Formulaire, 4 Groupes Item, 37 Eléments de données, 1 Langue

Groupes Item: Studieneinschluss, NIHSS und Modifizierte Rankin-Skala, Labor, Komplikationen zwischen Indexereignis und Studieneinschluss

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the inclusion form containing NIHSS, Rankin-Scale, laboratory values and complications.

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Cycle 1 - Week 4

- 13/10/2020 - 1 Formulaire, 9 Groupes Item, 163 Eléments de données, 1 Langue

Groupes Item: Date of visit, Assessment Date, Neurologic Examination, Neurologic Symptoms, Associated with, Neoplasms, Laboratory Procedures, Central Laboratory; Laboratory Procedures, Local, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Hematology finding, Central Laboratory, Data, Vital signs, Continuation status, Study

Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

Prodast Dabigatran NCT02507856 zentral follow up

- 16/05/2017 - 1 Formulaire, 13 Groupes Item, 198 Eléments de données, 1 Langue

Groupes Item: central follow up, Interview Patient/gesetzlicher Vertreter Allgemeine Fragen, Endpunkte I, Modifizierte Rankin-Skala (mRS), Endpunkte II, Endpunkte III, Antithrombotic Medication, Entlassmedikation abgesetzt, Neue antithrombotische Medikation, Die 10 letzten INR-Werte, AE und Bridging, Details, Befragungsende

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the zentral follow up form. https://clinicaltrials.gov/ct2/show/NCT02507856

Prodast Dabigatran NCT02507856 final event

- 05/04/2017 - 1 Formulaire, 1 Groupe Item, 44 Eléments de données, 1 Langue

Groupe Item: Endpunkt-Ereignis

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the final event form. https://clinicaltrials.gov/ct2/show/NCT02507856

Prodast Dabigatran NCT02507856 Serious Adverse Events

- 03/04/2017 - 1 Formulaire, 10 Groupes Item, 79 Eléments de données, 1 Langue

Groupes Item: Adverse Events, Patient Characteristics, Site address, Adverse Event, Pregnancy, Details Antithrombotic Product, Details Further Antithrombotic Product, Concomitant Therapies, Concomitant diagnoses, Comments

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the (serious) Adverse Events form. https://clinicaltrials.gov/ct2/show/NCT02507856

Prodast Dabigatran NCT02507856 Concomitant Therapy

- 03/04/2017 - 1 Formulaire, 1 Groupe Item, 14 Eléments de données, 1 Langue

Groupe Item: Concomitant Therapy

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the Concomitant Therapy form. https://clinicaltrials.gov/ct2/show/NCT02507856

Prodast Dabigatran NCT02507856 Procedures / Bridging

- 28/03/2017 - 1 Formulaire, 1 Groupe Item, 8 Eléments de données, 1 Langue

Groupe Item: Procedures

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the procedure/bridging form. https://clinicaltrials.gov/ct2/show/NCT02507856

Prodast Dabigatran NCT02507856 Antithrombotic Therapy

- 27/03/2017 - 1 Formulaire, 1 Groupe Item, 16 Eléments de données, 1 Langue

Groupe Item: Antithrombotische Therapie

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the discharge form containing Rankin-Scale, medication, laboratory values and cerebrovascular events. https://clinicaltrials.gov/ct2/show/NCT02507856

Prodast Dabigatran NCT02507856 Discharge

- 01/03/2017 - 1 Formulaire, 5 Groupes Item, 71 Eléments de données, 1 Langue

Groupes Item: Discharge, Modifizierte Rankin-Skala und Vitalparameter, Begleitmedikation zur Entlassung, Qualifizierendes zerebrovaskuläres Ereignis, Labor

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation. This is the discharge form containing Rankin-Scale, medication, laboratory values and cerebrovascular events.

Prodast Dabigatran NCT02507856 BookPRODAST

- 20/02/2017 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue

Groupes Item: Einwilligung, Dokumentation

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST) permission granted by Prof. Dr. Christian Weimar, University Hospital Essen The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral anticoagulation.

Mots-clés

Table des matières

Modèles de données sélectionnés